Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Glucocorticoids enhance the antileukemic activity of FLT3 inhibitors in FLT3-mutant acute myeloid leukemia

12 May 2020

Abstract excerpt

FLT3 is a frequently mutated gene that is highly associated with a poor prognosis in acute myeloid leukemia (AML). Despite initially responding to FLT3 inhibitors, most patients eventually relapse with drug resistance. The mechanism by which resistance arises and the initial response to drug treatment that promotes cell survival is unknown. Recent studies show that a transiently maintained subpopulation of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Epigenetics and DNA Methylation
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32396937
DOI: 10.1182/blood.2019003124

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Glucocorticoids enhance the antileukemic activity of FLT3 inhibitors in FLT3-mutant acute myeloid leukemiaPMID 32396937Read ↗

FLT3 inhibitors and novel therapeutic strategies to reverse AML resistance: An updated comprehensive review.Semantic proximity Read ↗

Overcoming Resistance to FLT3 Inhibitors in the Treatment of FLT3-Mutated AML.Semantic proximity Read ↗

Therapeutic targeting of FLT3 and associated drug resistance in acute myeloid leukemia.Semantic proximity Read ↗

LAM-003, a new drug for treatment of tyrosine kinase inhibitor-resistant FLT3-ITD-positive AML.Semantic proximity Read ↗

Hematopoietic cytokines mediate resistance to targeted therapy in FLT3-ITD acute myeloid leukemiaSemantic proximity Read ↗

Autophagy and inflammasome activation are associated with poor response to FLT3 inhibitors in patients with FLT3-ITD acute myeloid leukemia.Semantic proximity Read ↗

Enhanced sensitivity to glucocorticoids in cytarabine-resistant AMLSemantic proximity Read ↗

Mechanisms of Resistance to FLT3 Inhibitors and the Role of the Bone Marrow Microenvironment.Semantic proximity Read ↗

Evolving paradigms in targeting FLT3 for acute myeloid leukemia therapy.Semantic proximity Read ↗

The AML microenvironment catalyzes a stepwise evolution to gilteritinib resistanceSemantic proximity Read ↗

Autophagy and inflammasome molecular interplay and activation predict poor response to FLT3 inhibitors in patients with FLT3-ITD acute myeloid leukemiaSemantic proximity Read ↗

Synergistic effect of BCL2 and FLT3 co-inhibition in acute myeloid leukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.